Loading
Parasitic Diseases Research and Treatment / Mosquito Borne Diseases and Control · Journal article
Japanese Journal of Infectious Diseases · August 30, 2026
Early or partial results. Treat as a signal, not a conclusion.
This year-round prospective surveillance in Indonesia describes dengue epidemiology, serotype distribution, genotype characterization, and biomarker profiles in 240 confirmed cases. Secondary infection was associated with severe disease among hospitalized dengue patients (adjusted OR=10.25), but measured biomarkers did not discriminate severity and require validation in larger cohorts.
Year-round prospective surveillance study. Febrile patients aged ≥4 years presenting to a district hospital and two primary health centers in Tangerang Regency, Indonesia.. n = 404. Tangerang Regency, Indonesia.
Of 404 febrile participants, 240 (59.4%) had confirmed dengue Serotype distribution among 192 RT-PCR-serotyped cases: DENV-2 63/192 (32.8%), DENV-1 60/192 (31.3%), DENV-3 47/192 (24.5%), DENV-4 22/192 (11.5%) Among 144 hospitalized dengue cases, secondary infection in 131/144 (91.0%) was associated with severe disease (adjusted OR=10.25; 95% CI: 1.71-197.90, p=0.034)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The strong association between secondary dengue infection and severe disease (adjusted OR=10.25) supports clinical risk stratification based on infection history in endemic settings. However, measured biomarkers did not improve severity discrimination and require further validation before clinical adoption.
Year-round prospective surveillance describing epidemiology, clinical features, and biomarkers in a single-country, multi-site setting with confirmed dengue cases and serotype characterization, but limited generalizability and no intervention trial or hard clinical outcome comparison.
As stated by the source record.
Quoted from the source exactly as published.
The strong association between secondary dengue infection and severe disease (adjusted OR=10.25) supports clinical risk stratification based on infection history in endemic settings. However, measured biomarkers did not improve severity discrimination and require further validation before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Dengue remains a major public health concern in Indonesia. This study aimed to describe the epidemiology, clinical characteristics, immune responses, and genotype characterization of dengue virus (DENV) infections in Tangerang Regency, Indonesia. A year-round prospective surveillance was conducted from January 2024-January 2025 at a district hospital and two primary health centers. Febrile patients aged ≥4 years were tested using dengue NS1, IgM/IgG rapid tests, ELISA, and RT-PCR, and serum biomarkers (angiopoietin-2, IL-6, ferritin, sCD163) were quantified. Of 404 participants, 240 (59.4%) had confirmed dengue. Among RT-PCR-serotyped cases (n=192), the distribution was DENV-2 63/192 (32.8%), DENV-1 60/192 (31.3%), DENV-3 47/192 (24.5%), and DENV-4 22/192 (11.5%). Among hospitalized dengue cases (n=144), secondary infection (131/144, 91.0%) was associated with severe disease (adjusted OR=10.25; 95% CI: 1.71-197.90, p=0.034). Biomarker levels were elevated in dengue cases but did not discriminate severity, indicating the need for validation in larger cohorts using standardized definitions. Sequencing identified DENV-1 genotypes I and IV, DENV-2 Cosmopolitan, DENV-3 genotype I, and DENV-4 genotype IIa; one DENV-4 isolate carried an EDIII E384 D→H substitution warranting further investigation. Continued genomic surveillance and vaccine development that induces balanced, serotype-specific immunity are needed to support national and global dengue control.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.